VISEN Pharmaceuticals is a public biotech or pharmaceutical company listed on HKEX under the ticker 2561, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Latest VISEN Pharmaceuticals news
We have not published a story on VISEN Pharmaceuticals yet. When there is news, it will appear here.
Questions about VISEN Pharmaceuticals
What is the ticker symbol of VISEN Pharmaceuticals?
VISEN Pharmaceuticals trades under the ticker 2561 on HKEX.
Where is VISEN Pharmaceuticals listed?
VISEN Pharmaceuticals is listed on HKEX.
Which country or territory is VISEN Pharmaceuticals listed under?
Our directory records VISEN Pharmaceuticals under China.
What does VISEN Pharmaceuticals do?
Our directory classifies VISEN Pharmaceuticals as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of VISEN Pharmaceuticals?
The ISIN recorded for VISEN Pharmaceuticals is KYG93Y5D1039.
Does aibio.space cover VISEN Pharmaceuticals?
aibio.space lists VISEN Pharmaceuticals among 2,820 public biotech companies and publishes its news here as stories appear.
Which companies are similar to VISEN Pharmaceuticals?
Companies in our directory listed in the same country and business area as VISEN Pharmaceuticals: Beijing Foyou Pharma Co., Shandong Wohua Pharmaceutical Co., Harbin Gloria Pharmaceuticals Co., Jiangsu Nhwa Pharmaceutical Co., Transcenta Holding, Mabwell (Shanghai) Bioscience Co..
Investor discussion: VISEN Pharmaceuticals
Members talk about VISEN Pharmaceuticals (2561). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at VISEN Pharmaceuticals, newest first. Each line links the filing it comes from.
Financings
Share or debt issue: (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;
(2) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND SELL OR TRANSFER TREASURY SHARES;
(3) PROPOSED RE-APPOINTMENT OF AUDITOR;
AND (4) NOTICE OF ANNUAL GENERAL MEETING. Source
Financings
Share or debt issue: (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;
(2) PROPOSED GRANTING OF GENERAL MANDATES TO
REPURCHASE SHARES AND TO ISSUE SHARES AND
SELL OR TRANSFER TREASURY SHARES;
(3) PROPOSED RE-APPOINTMENT OF AUDITOR;
AND
(4) NOTICE OF ANNUAL GENERAL MEETING. Source
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:2561 on TradingView.
Listing details
VISEN Pharmaceuticals is a public biotech or pharmaceutical company listed on HKEX under the ticker 2561, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio